نتایج جستجو برای: feiba

تعداد نتایج: 75  

2009
Cezary Wójcik Michelle L. Schymik Eric G. Cure

AIMS The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care center. METHODS In this report we present a retrospective chart review of 72 patients who receive...

Journal: :Pathophysiology of haemostasis and thrombosis 2002
J T Wilde

FEIBA and Autoplex T have been used to control bleeding in patients with factor VIII or IX inhibitors for over 25 years. The major components of FEIBA are thought to be activated factor X and prothrombin, whereas the main active components in Autoplex T are thought to be activated factors IX and VII. Both products have been found to effectively control approximately 80% of bleeds involving join...

2016
Claude Negrier Sophie Voisin Fariba Baghaei Robert Numerof Aaron Novack Jennifer E. Doralt Vadim Romanov Alessandro Gringeri

This prospective, Post-Authorization Safety Surveillance (PASS) study was carried out in patients with hemophilia A or B and inhibitors treated with FEIBA for 1 year to collect real-world data on safety and effectiveness of FEIBA. The study followed a cohort design and did not make stipulations on treatment or observation schedule, as it was designed to observe routine medical practices based o...

2014
S V Antunes S Tangada O Stasyshyn V Mamonov J Phillips N Guzman-Becerra A Grigorian B Ewenstein W-Y Wong

Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti-inhibitor coagulant complex, Factor Eight Inhibitor Bypassing Activity (FEIBA NF), is a key therapeutic option for controlling acute haemorrhages in patients with high-ti...

Journal: :Journal of cardiothoracic and vascular anesthesia 2014
Vidya K Rao Robert L Lobato Blake Bartlett Mark Klanjac Christina T Mora-Mangano P David Soran Daryl A Oakes Charles C Hill Pieter J van der Starre

OBJECTIVE Postcardiopulmonary bypass hemorrhage remains a serious complication of cardiac surgery. Given concerns regarding adverse effects of blood product transfusion and limited efficacy of current antifibrinolytics, procoagulant medications, including recombinant factor VIIa (rFVIIa) and factor eight inhibitor bypass activity (FEIBA), increasingly have been used in managing refractory bleed...

Journal: :Anesthesiology 2014
Anthony M-H Ho

Vienna, Austria) as a quick reversal agent in emergency situations. Levy et al. cited the study by Marlu et al.2 but made no mention of the results on FEIBA as a reversal agent reported in that study and chose only to discuss the results on prothrombin complex concentrate and recombinant factor VIIa, while acknowledging that there is an activated form of 4-factor prothrombin complex concentrate...

2016
K. M. Sudheesh K. S. N. Siva Bharani H. Y. Kiran Suresh Hanagavadi

Dental extraction in hemophiliacs with acquired inhibitors is always a risky procedure, which often presents a lot of problems associated with bleeding. A known case of hemophilia A complicated with factor VIII inhibitors and having odontogenic infection was successfully managed by transfusion of factor VIII inhibitor bypass activity (FEIBA) and antihemophilic factor. Past medical history was s...

2016
Mina Golestani Peyman Eshghi Hamid Reza Rasekh Abdoll Majid Cheraghali Jamshid Salamzadeh Majid Naderi Mohammad Reza Managhchi Hamid Hoorfar Gholam Reza Toogeh Ali Imani Mohammad Taghi Khodayari Behnaz Habibpanah Razieh Hantooshzadeh

Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost-effectiv...

Journal: :Blood 2007
Jan Astermark Sharyne M Donfield Donna M DiMichele Alessandro Gringeri Steven A Gilbert Jennifer Waters Erik Berntorp

The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors. The FENOC study was designed to test equivalence of the products in th...

2006
Jan Astermark Sharyne M. Donfield Donna M. DiMichele Alessandro Gringeri Steven A. Gilbert Jennifer Waters Erik Berntorp

The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitorbypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors. The FENOC study was designed to test equivalence of the products in the...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید